Item 8.01. Other Events.

On January 21, 2020, BeiGene, Ltd. (the "Company") announced that the pivotal Phase 3 trial evaluating its anti-PD-1 antibody tislelizumab in combination with two chemotherapy regimens for the first-line treatment of patients with squamous non-small cell lung cancer (NSCLC), met the primary endpoint of improved progression-free survival (PFS) at the planned interim analysis, as assessed by independent review committee (IRC). A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.


Exhibit No.                               Description
99.1           Press release issued by the Company on January 21, 2020
               The cover page from this Current Report on Form 8-K, formatted in
 104           Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses